Opioid Resource Center
Opioid Resource Center
October 19, 2017
1 min read

Extended-release naltrexone comparable to buprenorphine-naloxone for opioid addiction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Extended-release naltrexone had comparable efficacy to a combination of buprenorphine and naloxone for maintaining short-term abstinence from heroin and other illicit substances among opioid-dependent individuals.

“Because of the injection-deterring potential of naloxone hydrochloride and the better safety profile compared with methadone, daily administration of combined buprenorphine and naloxone (buprenorphine-naloxone) is the first choice of [opioid medication treatment] medication in a number of countries. However, the extent to which buprenorphine-naloxone deters injection in practice has been debated,” Lars Tanum, MD, DMSci, of the University of Oslo, Norway, and colleagues wrote.

To compare efficacy of extended-release naltrexone with daily buprenorphine-naloxone for maintaining abstinence from heroin and other illicit substances, researchers conducted a 12-week, multicenter, outpatient, open-label randomized clinical trial at five urban addiction clinics in Norway. Study participants were randomly assigned to receive daily oral flexible dose buprenorphine-naloxone (n = 79) or extended-release naltrexone hydrochloride (n = 80) administered intramuscularly every fourth week for 12 weeks. Participants had a mean age of 36 years.

Retention was comparable between participants who received extended-release naltrexone or buprenorphine-naloxone (difference = –0.1; 95% CI, –0.2 to 0.1), with mean time of 69.3 days and 63.7 days, respectively.

Treatment with extended-release naltrexone was noninferior to buprenorphine-naloxone for group proportion of total number of opioid-negative urine tests (difference = 0.1; 95% CI, –0.04 to 0.2), heroin use (mean difference = –3.2; 95% CI, –4.9 to –1.5) and other illicit substance use (mean difference = –2.7; 95% CI, –4.6 to –0.9).

Superiority analysis indicated significantly lower use of heroin and illicit opioids among participants who received extended-release naltrexone.

There were no other significant differences between treatment groups regarding most other illicit substances.

“Maintaining short-term abstinence from illicit opioids and other substances with extended-release naltrexone was as effective and safe as buprenorphine-naloxone. Extended-release naltrexone should be an available treatment option for opioid-dependent individuals,” the researchers concluded. – by Amanda Oldt

Disclosures: The authors report no relevant financial disclosures.